...
首页> 外文期刊>Journal of Clinical Microbiology >Analytical and Clinical Evaluation of the Epistem Genedrive Assay for Detection of Mycobacterium tuberculosis
【24h】

Analytical and Clinical Evaluation of the Epistem Genedrive Assay for Detection of Mycobacterium tuberculosis

机译:结核分枝杆菌Epistem基因驱动检测的分析和临床评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The Epistem Genedrive assay rapidly detects the Mycobacterium tuberculosis complex from sputum and is currently available for clinical use. However, the analytical and clinical performance of this test has not been fully evaluated. The analytical limit of detection (LOD) of the Genedrive PCR amplification was tested with genomic DNA; the performance of the complete (sample processing plus amplification) system was tested by spiking M. tuberculosis mc26030 cells into distilled water and M. tuberculosis-negative sputum. Specificity was tested using common respiratory pathogens and nontuberculosis mycobacteria. A clinical evaluation enrolled adults with suspected pulmonary tuberculosis, obtained three sputum samples from each participant, and compared the accuracy of the Genedrive to that of the Xpert MTB/RIF assay using M. tuberculosis cultures as the reference standard. The Genedrive assay had an LOD of 1 pg/μl (100 genomic DNA copies/reaction). The LODs of the system were 2.5 × 104 CFU/ml and 2.5 × 105 CFU/ml for cells spiked into water and sputum, respectively. False-positive rpoB probe signals were observed in 3/32 (9.4%) of the negative controls and also in few samples containing Mycobacterium abscessus, Mycobacterium gordonae, or Mycobacterium thermoresistibile. In the clinical study, among 336 analyzed participants, the overall sensitivities for the tuberculosis case detection of Genedrive, Xpert, and smear microscopy were 45.4% (95% confidence interval [CI], 35.2% to 55.8%), 91.8% (95% CI, 84.4% to 96.4%), and 77.3% (95% CI, 67.7% to 85.2%), respectively. The sensitivities of Genedrive and Xpert for the detection of smear-microscopy-negative tuberculosis were 0% (95% CI, 0% to 15.4%) and 68.2% (95% CI, 45.1% to 86.1%), respectively. The Genedrive assay did not meet performance standards recommended by the World Health Organization for a smear microscopy replacement tuberculosis test. Epistem is working on modifications to improve the assay.
机译:Epistem Genedrive分析可快速检测出痰中的结核分枝杆菌复合物,目前可用于临床。但是,该测试的分析和临床性能尚未得到充分评估。用基因组DNA检测了Genedrive PCR扩增的检测限(LOD)。通过将结核分枝杆菌mc 2 6030细胞掺入蒸馏水和结核分枝杆菌阴性痰液中来测试完整系统(样品处理和扩增)的性能。使用常见的呼吸道病原体和非结核分枝杆菌测试特异性。一项临床评估招募了患有疑似肺结核的成年人,从每个参与者中获取了三份痰标本,并使用结核分枝杆菌培养物作为参考标准,将Genedrive的准确性与Xpert MTB / RIF分析的准确性进行了比较。 Genedrive检测的LOD为1 pg /μl(100个基因组DNA拷贝/反应)。对于掺入水和痰中的细胞,系统的LOD分别为2.5×10 4 CFU / ml和2.5×10 5 CFU / ml。在3/32(9.4%)的阴性对照以及少数含有脓肿分枝杆菌,戈登分枝杆菌或抗热分枝杆菌的样品中观察到假阳性 rpoB 探针信号。在临床研究中,在336名被分析的参与者中,对基因驱动,Xpert和涂片显微镜检查进行结核病例检测的总体敏感性分别为45.4%(95%置信区间[CI],35.2%至55.8%),91.8%(95%) CI分别为84.4%至96.4%)和77.3%(95%CI为67.7%至85.2%)。 Genedrive和Xpert检测涂片镜检阴性结核的敏感性分别为0%(95%CI,0%至15.4%)和68.2%(95%CI,45.1%至86.1%)。 Genedrive分析不符合世界卫生组织推荐的涂片显微镜替代结核试验的性能标准。 Epistem正在致力于改进检测方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号